Corona rapid test from GNA Biosolutions approved

The Bavarian start-up's rapid test is expected to deliver a result in less than an hour.
The German Federal Institute for Drugs and Medical Devices (BfArM) has granted special approval to the Corona rapid test developed by the Bavarian start-up GNA Biosolutions, which specialises in molecular diagnostics. The test is said to provide the correct result in 96.7 percent of cases and takes only 40 minutes. Another advantage: according to the manufacturer, decentralized laboratories are sufficient for this.
Unlike the most commonly used rapid antigen tests, GNA Biosolutions' test is based on the PCR test and therefore provides more accurate results. The start-up uses Pulse Controlled Amplification (PCA®) technology, a new approach to polymerase chain reaction (PCR), the global standard for COVID-19 molecular testing.

"In order to make our technology available across Europe, we are aiming for a CE mark in the first quarter of 2021," says CEO and co-founder Dr. Federico Buersgens. The start-up from Martinsried near Munich received funding from the Bavarian Ministry of Economic Affairs for its development. Now more than 500,000 tests are to be produced.

Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectTake care, give care
Did this news inform or entertain you? Then we would be happy if you tell your network about it.
Share on Linkedin Share on Facebook Share on XingRelated companies

FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?